ASRT Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$24.43median target· current $23.50 (+4.0%)4 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 56.50
EPS (TTM)$-5.55-18.8% YoY
Profit margin-34.9%HEALTHCARE
Market cap$151.9MMicro cap
Valuation
- Forward P/E
- 56.50
- PEG ratio
- 1.50
- P/B
- 2.01
- P/S (TTM)
- 1.49
- EV/EBITDA
- 45.69
Profitability & growth
- ROE (TTM)
- -38.8%
- Operating margin
- -185.9%
- Revenue growth YoY
- -62.5%
- Dividend yield
- —
- Beta
- 0.53
Last earnings
May 8, 2026 · Estimate $-1.91 · Reported $-2.93
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Assertio Therapeutics Inc
Company profileAssertio Holdings, Inc., a commercial pharmaceutical company, provides medications in the areas of neurology, hospital, and pain and inflammation. The company is headquartered in Lake Forest, Illinois.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 100 SOUTH SAUNDERS ROAD, LAKE FOREST, IL
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$151.9M
Shares outstanding$6.5M
52W high$23.50
52W low$8.61
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent